nach oben

Diabetologia

Erschienen in:

01.05.2010 | Article

The impact of liver fat vs visceral fat in determining categories of prediabetes

verfasst von: K. Kantartzis, J. Machann, F. Schick, A. Fritsche, H.-U. Häring, N. Stefan

Erschienen in: Diabetologia | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) are risk factors for type 2 diabetes and cardiovascular disease; however, their impact on these endpoints differs. Because liver fat and visceral fat are important determinants of glucose and lipid metabolism, we investigated whether these fat compartments and their humoral products, the adipokine adiponectin and the hepatokine fetuin-A, differ in their impact on the glucose categories.

Methods

In 330 individuals at risk of type 2 diabetes, glucose tolerance status was determined by a 2 h 75 g OGTT. Total-body and visceral fat were precisely quantified by magnetic resonance (MR) tomography and liver fat by ¹H-MR spectroscopy.

Results

A total of 210 individuals had normal glucose tolerance (NGT), 41 isolated IFG, 43 isolated IGT and 36 IFG+IGT. Total-body fat was not different (p = 0.51), although a small but continuous increase in visceral fat was found among the categories after adjustment for age and sex (NGT: 3.07 ± 0.10 kg; IFG: 3.11 ± 0.21 kg; IGT: 3.61 ± 0.21 kg; IFG+IGT: 3.84 ± 0.23 kg [SEs], p = 0.03). A larger difference was found for liver fat (NGT: 4.73 ± 0.42%; IFG: 5.86 ± 0.92%; IGT: 8.65 ± 0.92%; IFG + IGT: 11.11 ± 1.01%, p < 0.0001). The differences among the categories were small for adiponectin (p = 0.14), but larger for fetuin-A (p = 0.015). Among fat compartments, liver fat (p < 0.0001) and among circulating variables fetuin-A (p = 0.016) were the strongest determinants of the categories.

Conclusions/interpretation

Liver fat, more than visceral fat, strongly increases when glycaemia and glucose tolerance move from NGT to isolated IFG, isolated IGT and IFG+IGT. Because liver-derived circulating fetuin-A determines, although weakly, prediabetes categories, it is worth searching for hepatokines more strongly predicting prediabetes.

Laakso M, Zilinskaite J, Hansen T et al (2008) Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 Study. Diabetologia 51:502–511CrossRefPubMed

Abdul-Ghani MA, Tripathy D, DeFronzo RA (2006) Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130–1139CrossRefPubMed

Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M (2009) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 58:1212–1221CrossRefPubMed

Meyer C, Pimenta W, Woerle HJ et al (2006) Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 29:1909–1914CrossRefPubMed

Nathan DM, Davidson MB, DeFronzo RA et al (2007) Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 30:753–759CrossRefPubMed

Kim NH, Pavkov ME, Looker HC et al (2008) Plasma glucose regulation and mortality in pima Indians. Diabetes Care 31:488–492CrossRefPubMed

Meigs JB, Nathan DM, D’Agostino RB Sr, Wilson PW (2002) Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845–1850CrossRefPubMed

Sorkin JD, Muller DC, Fleg JL, Andres R (2005) The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: data from the Baltimore Longitudinal Study of Aging with a critical review of the literature. Diabetes Care 28:2626–2632CrossRefPubMed

Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K (2004) Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 47:2118–2128CrossRefPubMed

10.

Anon (1999) Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet 354:617–621CrossRef

11.

Stern MP, Fatehi P, Williams K, Haffner SM (2002) Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care 25:1851–1856CrossRefPubMed

12.

Wajchenberg BL (2000) Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21:697–738CrossRefPubMed

13.

Despres JP, Lemieux I (2006) Abdominal obesity and metabolic syndrome. Nature 444:881–887CrossRefPubMed

14.

Roden M (2006) Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2:335–348CrossRefPubMed

15.

Stefan N, Kantartzis K, Haring HU (2008) Causes and metabolic consequences of fatty liver. Endocr Rev 29:939–960CrossRefPubMed

16.

Targher G, Bertolini L, Padovani R et al (2006) Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29:1325–1330CrossRefPubMed

17.

Kotronen A, Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRefPubMed

18.

Targher G, Marra F, Marchesini G (2008) Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 51:1947–1953CrossRefPubMed

19.

Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168:1609–1616CrossRefPubMed

20.

Karelis AD (2008) Metabolically healthy but obese individuals. Lancet 372:1281–1283CrossRefPubMed

21.

Kantartzis K, Rittig K, Balletshofer B et al (2006) The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. Clin Chem 52:1934–1942CrossRefPubMed

22.

Stefan N, Hennige AM, Staiger H et al (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29:853–857CrossRefPubMed

23.

Trujillo ME, Scherer PE (2006) Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27:762–778PubMed

24.

Stefan N, Fritsche A, Weikert C et al (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57:2762–2767CrossRefPubMed

25.

Weikert C, Stefan N, Schulze MB et al (2008) Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118:2555–2562CrossRefPubMed

26.

Ix JH, Wassel CL, Kanaya AM et al (2008) Fetuin-A and incident diabetes mellitus in older persons. JAMA 300:182–188CrossRefPubMed

27.

Fisher E, Stefan N, Saar K et al (2009) Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam Study. Circ Cardiovasc Genet 2:607–613CrossRefPubMed

28.

Kantartzis K, Thamer C, Peter A et al (2009) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58:1281–1288CrossRefPubMed

29.

Stefan N, Machicao F, Staiger H et al (2005) Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologia 48:2282–2291CrossRefPubMed

30.

Genuth S, Alberti KG, Bennett P et al (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167CrossRefPubMed

31.

Forouhi NG, Balkau B, Borch-Johnsen K et al (2006) The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group. Diabetologia 49:822–827CrossRefPubMed

32.

Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed

33.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed

34.

Staiger H, Machicao F, Kantartzis K et al (2008) Novel meta-analysis-derived type 2 diabetes risk loci do not determine prediabetic phenotypes. PLoS ONE 3:e3019CrossRefPubMed

35.

Szczepaniak LS, Nurenberg P, Leonard D et al (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288:E462–E468CrossRefPubMed

36.

Kelley DE, McKolanis TM, Hegazi RA, Kuller LH, Kalhan SC (2003) Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. Am J Physiol Endocrinol Metab 285:E906–E916PubMed

37.

Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735–2752CrossRefPubMed

38.

Cali AM, de Oliveira AM, Kim H et al (2009) Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology 49:1896–1903CrossRefPubMed

39.

Utzschneider KM, Kahn SE (2006) Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 91:4753–4761CrossRefPubMed

40.

Szendroedi J, Roden M (2009) Ectopic lipids and organ function. Curr Opin Lipidol 20:50–56CrossRefPubMed

41.

Perseghin G, Bonfanti R, Magni S et al (2006) Insulin resistance and whole body energy homeostasis in obese adolescents with fatty liver disease. Am J Physiol Endocrinol Metab 291:E697–E703CrossRefPubMed

42.

Samuel VT, Liu ZX, Qu X et al (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345–32353CrossRefPubMed

43.

Kantartzis K, Fritsche A, Tschritter O et al (2005) The association between plasma adiponectin and insulin sensitivity in humans depends on obesity. Obes Res 13:1683–1691CrossRefPubMed

44.

Faerch K, Vaag A, Holst JJ, Hansen T, Jorgensen T, Borch-Johnsen K (2009) Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 Study. Diabetes Care 32:439–444CrossRefPubMed

45.

Tushuizen ME, Bunck MC, Pouwels PJ, Bontemps S, Mari A, Diamant M (2008) Lack of association of liver fat with model parameters of beta-cell function in men with impaired glucose tolerance and type 2 diabetes. Eur J Endocrinol 159:251–257CrossRefPubMed

46.

Rijkelijkhuizen JM, Doesburg T, Girman CJ et al (2009) Hepatic fat is not associated with beta-cell function or postprandial free fatty acid response. Metabolism 58:196–203CrossRefPubMed

47.

McCullough AJ (2004) The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 8:521–533, viii

48.

Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355:2297–2307CrossRefPubMed

49.

Riserus U, Sprecher D, Johnson T et al (2008) Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. Diabetes 57:332–339CrossRefPubMed

50.

Thamer C, Machann J, Stefan N et al (2008) Variations in PPARD determine the change in body composition during lifestyle intervention: a whole-body magnetic resonance study. J Clin Endocrinol Metab 93:1497–1500CrossRefPubMed

Titel: The impact of liver fat vs visceral fat in determining categories of prediabetes
verfasst von: K. Kantartzis
J. Machann
F. Schick
A. Fritsche
H.-U. Häring
N. Stefan
Publikationsdatum: 01.05.2010
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 5/2010
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-010-1663-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Skin and soft tissue infections in hospitalised patients with diabetes: culture isolates and risk factors associated with mortality, length of stay and cost

Folic acid administration reduces neointimal thickening, augments neo-vasa vasorum formation and reduces oxidative stress in saphenous vein grafts from pigs used as a model of diabetes

Rat islet cell aggregates are superior to islets for transplantation in microcapsules

Could recombinant insulin compounds contribute to adenocarcinoma progression by stimulating local angiogenesis?